Vanda Pharmaceuticals Inc. — Director's Dealing 2020

Jun 2, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2020-05-29

Reporting Person: Watkins Thomas (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-29	Common Stock	M	15000	$7.38	Acquired	45000	Direct
2020-05-29	Common Stock	S	9677	$11.50	Disposed	35323	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-29	Nonstatutory Stock Option (Right to Buy)	$7.38	M	15000	Disposed	2020-06-02	Common Stock (15000)	Direct

Footnotes

F1: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire June 2, 2020 as reflected in this Form 4.

F2: The option vested in 12 equal monthly installments beginning on July 3, 2010.